Vipadenant – 500 µg

Brand:
Cayman
CAS:
442908-10-3
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Vipadenant is a selective adenosine 2A (A2A) receptor antagonist with Ki values of 1.3, 68, 63, and 1,005 nM for A2A, A1, A2B, and A3 receptors, respectively, in a radioligand binding assay.{38172} It acts as a functional antagonist of human recombinant A2A (KA = 0.58 nM) in a calcium mobilization-based FLIPR assay. Vipadenant also reverses haloperidol-induced hypolocomotion in mice and rats. Formulations containing vipadenant are under clinical investigation for the treatment of symptoms associated with Parkinson’s disease.{38172,38173}  

 

Available on backorder

SKU: 20239 - Category:

Description

A selectve adenosine A2A receptor antagonist (Kis = 1.3, 68, 63, and 1,005 nM for A2A, A1, A2B, and A3 receptors, respectively in a radio ligand binding assay); acts as a functional antagonist of human recombinant A2A (KA = 0.58 nM) in a calcium mobilization-based FLIPR assay; reverses haloperidol-induced hypolocomotion in mice and rats,


Formal name: 3-[(4-amino-3-methylphenyl)methyl]-7-(2-furanyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-amine

Synonyms:  BIIB-014

Molecular weight: 321.3

CAS: 442908-10-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease